Dakota Wealth Management Decreases Position in Edwards Lifesciences Co. (NYSE:EW)

Dakota Wealth Management trimmed its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 59.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,877 shares of the medical research company’s stock after selling 8,566 shares during the period. Dakota Wealth Management’s holdings in Edwards Lifesciences were worth $388,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Assenagon Asset Management S.A. increased its stake in shares of Edwards Lifesciences by 12.4% in the third quarter. Assenagon Asset Management S.A. now owns 737,090 shares of the medical research company’s stock worth $48,641,000 after buying an additional 81,470 shares during the period. Bogart Wealth LLC increased its position in shares of Edwards Lifesciences by 8.8% in the third quarter. Bogart Wealth LLC now owns 67,111 shares of the medical research company’s stock valued at $4,429,000 after acquiring an additional 5,408 shares during the period. Mason & Associates Inc raised its stake in shares of Edwards Lifesciences by 78.2% during the third quarter. Mason & Associates Inc now owns 7,882 shares of the medical research company’s stock valued at $520,000 after acquiring an additional 3,460 shares during the last quarter. Patrick M Sweeney & Associates Inc. boosted its holdings in shares of Edwards Lifesciences by 20.1% during the third quarter. Patrick M Sweeney & Associates Inc. now owns 3,885 shares of the medical research company’s stock worth $256,000 after purchasing an additional 650 shares during the period. Finally, Spectrum Asset Management Inc. NB CA grew its stake in shares of Edwards Lifesciences by 1,346.4% in the third quarter. Spectrum Asset Management Inc. NB CA now owns 38,054 shares of the medical research company’s stock worth $2,511,000 after purchasing an additional 35,423 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Stock Down 1.2 %

NYSE:EW opened at $68.52 on Tuesday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71. The firm has a market cap of $41.29 billion, a P/E ratio of 29.53, a P/E/G ratio of 3.00 and a beta of 1.13. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The firm has a 50-day simple moving average of $68.10 and a two-hundred day simple moving average of $78.13.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The company had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same period in the previous year, the business earned $0.59 EPS. The firm’s revenue for the quarter was up 8.9% on a year-over-year basis. Analysts predict that Edwards Lifesciences Co. will post 2.61 earnings per share for the current fiscal year.

Insider Activity

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total value of $330,400.00. Following the completion of the sale, the vice president now directly owns 46,936 shares in the company, valued at $3,101,530.88. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total value of $330,400.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,101,530.88. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Daveen Chopra sold 1,250 shares of the stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the transaction, the vice president now directly owns 29,333 shares in the company, valued at approximately $2,051,843.35. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 16,250 shares of company stock valued at $1,099,238 over the last ninety days. 1.29% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

EW has been the subject of a number of recent analyst reports. Daiwa America raised Edwards Lifesciences to a “strong-buy” rating in a research report on Wednesday, July 31st. Oppenheimer reaffirmed an “outperform” rating and issued a $90.00 price target on shares of Edwards Lifesciences in a research note on Thursday, September 12th. Jefferies Financial Group downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and reduced their price objective for the company from $85.00 to $70.00 in a research report on Wednesday, September 18th. Stifel Nicolaus decreased their price objective on shares of Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating for the company in a report on Thursday, July 25th. Finally, Wells Fargo & Company cut their target price on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday, September 9th. Fifteen analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $75.67.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.